ライフサイエンスコーパス: immunomodulatory therapy

1 seizure frequency was associated with use of immunomodulatory therapy.

2 e response of multiple sclerosis patients to immunomodulatory therapy.

3 odels, provides a target for diagnostics and immunomodulatory therapy.

4 rome, suggests a potential narrow target for immunomodulatory therapy.

5 combination of systemic corticosteroids and immunomodulatory therapy.

6 ng inflamed eyes being treated with systemic immunomodulatory therapy.

7 g as well as for development of prophylactic immunomodulatory therapy.

8 plastic AIR should be treated with long-term immunomodulatory therapy.

9 IR patients should be treated with long-term immunomodulatory therapy.

10 Thirty-seven patients received immunomodulatory therapy.

11 armacological inhibitors of ion channels for immunomodulatory therapy.

12 nic demyelinating optic neuropathy on stable immunomodulatory therapy.

13 a minimum of 3 months following a switch of immunomodulatory therapy.

14 ance can be overcome by autoantigen-specific immunomodulatory therapy.

15 glecs could provide novel targets for cancer immunomodulatory therapy.

16 ur cohort of patients who received frontline immunomodulatory therapy.

17 uveitis when used as an adjuvant to systemic immunomodulatory therapy.

18 (22/25) when used as an adjuvant to systemic immunomodulatory therapy.

19 bidity despite continuous systemic and local immunomodulatory therapy.

20 fied short-term to chronic antibiotic and/or immunomodulatory therapy.

21 IVIg is widely used as an immunomodulatory therapy.

22 gets, and as such are attractive targets for immunomodulatory therapy.

23 hosphate lyase may be a potential target for immunomodulatory therapy.

24 ssues to better inform future application of immunomodulatory therapies.

25 ion, suggesting a direction for pro-tolerant immunomodulatory therapies.

26 with OCD and tic disorders will benefit from immunomodulatory therapies.

27 documenting immune responses in studies for immunomodulatory therapies.

28 ing tolerance of skin may require additional immunomodulatory therapies.

29 ction without the requirement of vaccines or immunomodulatory therapies.

30 nment on the final outcome of antibody-based immunomodulatory therapies.

31 These conditions often improve following immunomodulatory therapies.

32 to identify patients who would benefit from immunomodulatory therapies.

33 inflammation continues with greater focus on immunomodulatory therapies.

34 ma either alone or in combination with these immunomodulatory therapies.

35 hich suggests ZAP-70 as a logical target for immunomodulatory therapies.

36 will be additive or synergistic with current immunomodulatory therapies.

37 of human DCs, presenting a unique target for immunomodulatory therapies.

38 sponse and therefore is a logical target for immunomodulatory therapies.

39 ddress this issue in the context of lymphoma immunomodulatory therapy, a workshop was convened to pro

40 new population niches owing to the advent of immunomodulatory therapies and increased numbers of pati

41 ttern, development of effective antiviral or immunomodulatory therapies and vaccines should become sc

42 sence of major comorbidities, treatment with immunomodulatory therapy and disruption of the microbiom

43 onparaneoplastic AIR patients with long-term immunomodulatory therapy and that there is enough equipo

44 e of his or her disease for consideration of immunomodulatory therapy, and will require legislation m

45 Antiangiogenic and immunomodulatory therapies are gaining momentum in the p

46 However, attempts at introducing various immunomodulatory therapies as a new treatment strategy h

47 c immunoglobulins are used as replacement or immunomodulatory therapy, but can transmit clinically im

48 Prospective controlled clinical trials with immunomodulatory therapy can help define future treatmen

49 heson 2014 criteria and LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC) (2016 revised

50 s of monoclonal antibody therapies and other immunomodulatory therapies currently being contemplated

51 The responses to immunomodulatory therapies, defined by changes in modifi

52 entially reversible, justifying early use of immunomodulatory therapy directed at lowering IgG levels

53 Currently available immunomodulatory therapies do not stop the pathogenesis

54 Although 12 immunomodulatory therapies exist, they have only modest

55 Despite the immunogenicity of melanoma, immunomodulatory therapies fail in the majority of patie

56 d improved design of cytokine based clinical immunomodulatory therapies for cancer and infectious dis

57 evelopment of specific, clinically available immunomodulatory therapies for Graves eye disease.

58 IDS but also occurs in individuals receiving immunomodulatory therapies for immune-related diseases s

59 by donor human leukocyte antigens (HLA), new immunomodulatory therapies for organ-transplant recipien

60 findings suggest that future studies seeking immunomodulatory therapies for preterm infants should co

61 hese developments highlight the potential of immunomodulatory therapies for treatment of these condit

62 ects of chronic MS and had not been received immunomodulatory therapy for MS.

63 Lactate could be a promising immunomodulatory therapy for patients with acute organ i

64 who are considering lymphocytotoxic or other immunomodulatory therapy for RA.

65 IFN-beta-1b is a first-line immunomodulatory therapy for relapsing-remitting multipl

66 ficant limitations of rhIL-10 as a potential immunomodulatory therapy for sepsis.

67 Recent studies have shown that immunomodulatory therapy for the treatment of rheumatic

68 The utility of immunomodulatory therapy for this condition remains unkn

69 High-dose i.v. Ig (IVIg) is a prominent immunomodulatory therapy for various autoimmune and infl

70 Immunomodulatory therapy has been associated with better

71 As a result, new immunomodulatory therapies have been used to treat stero

72 Existing immunomodulatory therapies have had limited effects on p

73 gs (SAIDs), immunosuppressive therapy drugs (immunomodulatory therapy [IMT]), or biologic response mo

74 in tau and raising concerns about the use of immunomodulatory therapies in AD.

75 the potential to guide optimal selection of immunomodulatory therapies in individual patients and mo

76 om existing experience with the use of these immunomodulatory therapies in other conditions and that

77 firmed by the differential susceptibility to immunomodulatory therapies in vivo.

78 e implications of these cases for the use of immunomodulatory therapy in CD and the questionable asso

79 able in vivo model for examining the role of immunomodulatory therapy in modifying HIV infection.

80 mmunologists prepared to move on to systemic immunomodulatory therapy in those instances where the ch

81 Immunomodulatory therapy involving HTLV-1-infected patie

82 RECENT FINDINGS: Use of targeted biologic immunomodulatory therapy is becoming widespread and prov

83 The issue of attempting immunomodulatory therapy is discussed in view of the pub

84 autoimmune liver disease for which effective immunomodulatory therapy is lacking.

85 detrimental or beneficial, before developing immunomodulatory therapies, it is necessary to better un

86 n of oncogene-targeted therapy together with immunomodulatory therapy may be ideal for the developmen

87 Immunomodulatory therapy may not always be required.

88 When CpG was administered as immunomodulatory therapy prior to allergen sensitization

89 nsight into the design of clinical trials of immunomodulatory therapies, ranging from optimal patient

90 Immunomodulatory therapy represents an attractive approa

91 tivitis other than MMP, rather than systemic immunomodulatory therapy, resulting in irreversible clin

92 Immunomodulatory therapies should be investigated in adu

93 17 patients required immunomodulatory therapies, six improved spontaneously,

94 creates new translational possibilities for immunomodulatory therapies, specifically vaginal therapi

95 n inhibition might be a useful supplement to immunomodulatory therapies such as corticosteroids in ON

96 t investigations for diagnosis; conventional immunomodulatory therapies, such as interferon beta and

97 ves have been further studied, and promising immunomodulatory therapies, such as targeted B-cell ther

98 Immunomodulatory therapies targeting MMPs in preclinical

99 It highlights targets for future immunomodulatory therapy that may treat and potentially

100 esponse have fueled considerable interest in immunomodulatory therapy, the role of such agents in cli

101 micro- and nanoparticles are often added to immunomodulatory therapies to enhance the triggered immu

102 gun, with the possibility of designing novel immunomodulatory therapies to intervene with neuroinflam

103 gether, our data highlight the potential for immunomodulatory therapies to stimulate alveologenesis i

104 y IL-1 response could be used as a potential immunomodulatory therapy to improve the outcome of asper

105 e spread of nodal metastases and the role of immunomodulatory therapy to prevent or possibly even rev

106 optive T-cell therapy development as well as immunomodulatory therapy tools available for immediate c

107 nd innovative strategies, including targeted immunomodulatory therapies, tyrosine kinase inhibitors a

108 Emerging evidence suggests that immunomodulatory therapies used in nephrotic syndrome di

109 ficantly influences its response to numerous immunomodulatory therapies used in organ transplantation

110 Prednisone doses before and after immunomodulatory therapy were compared.

111 ectious scleritis refractory to conventional immunomodulatory therapy who were seen at the Massachuse

112 The data support the potential for immunomodulatory therapy with CpG in early life to reduc

113 en antibiotic treatment, but not biologic or immunomodulatory therapy, with reduced proportions of 11